CD274 and neoplasm: As all high-risk patients included in our cohort had underlying haematological malignancies, knowing more about the possible anti-tumour and anti-fungal synergy of immune checkpoint inhibitors in these patients and its effect on the PD-L1 expression in their serum and BALf would be very interesting.